Skip Navigation


Hum. Reprod. Advance Access originally published online on July 16, 2009
Human Reproduction 2009 24(10):2389-2394; doi:10.1093/humrep/dep246
This Article
Right arrow Full Text
Right arrow Full Text (PDF )
Right arrow All Versions of this Article:
24/10/2389    most recent
dep246v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in Hum. Reprod.
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Humaidan, P.
Right arrow Articles by Tarlatzis, B.C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Humaidan, P.
Right arrow Articles by Tarlatzis, B.C.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

OPINION

GnRHa to trigger final oocyte maturation: a time to reconsider

P. Humaidan1,3, E.G. Papanikolaou2 and B.C. Tarlatzis2

1 The Fertility Clinic, Skive Regional Hospital, DK 7800 Skive, Denmark 2 Biogenesis, Assisted Reproduction Unit, Thessaloniki, Greece

3 Correspondence address. E-mail: peter.humaidan{at}sygehusviborg.dk

Recently GnRH antagonist protocols for the prevention of a premature LH surge were introduced, allowing final oocyte maturation to be triggered with a single bolus of a GnRH agonist (GnRHa). GnRHa is as effective as hCG for the induction of ovulation, and apart from the LH surge a FSH surge is also induced. Until recently, prospective randomized studies reported a poor clinical outcome when GnRHa was used to trigger final oocyte maturation in IVF/ICSI antagonist protocols, presumably due to a luteal phase deficiency, despite standard luteal phase supplementation with progesterone and estradiol. As GnRHa triggering of final oocyte maturation could possess advantages over hCG triggering in terms of a reduced if not eliminated risk of ovarian hyperstimulation syndrome (OHSS) and the retrieval of more mature oocytes, the challenge has been to rescue the luteal phase. In the literature now several studies report a luteal phase rescue with a reproductive outcome comparable to that of hCG induced final oocyte maturation. Although more research is needed, GnRHa triggering is now a valid alternative with potential benefits.

Key words: GnRH agonist/GnRH antagonist/hCG/LH/In vitro fertilization


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related articles in Hum. Reprod.:

Editor's Choice
Andre Van Steirteghem
Hum. Reprod. 2009 24: 2387-2388. [Extract] [Full Text]  





Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.